University of Valladolid   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Valladolid Spain (1241)

Organization Overview

First Clinical Trial
2008
NCT00748787
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Dr. Luis Fernandez | Hospital Clínico Universitario de Valladolid | Hospital Clinico Universitario, Valladolid | Hospital Universitario de Valladolid | IBGM, University of Valladolid | Scientific Park Foundation of University of Valladolid | Service of Endocrinology and Nutrition. Clinic Hospital University of Valladolid | Universitario Valladolid | University Clinical Hospital of Valladolid | University of Valladolid | University of Valladolid, Scientific Park | University of Valladolid, Spain | Valladolid UNIVERSITY CLINICAL HOSPITAL

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Back Pain (Phase 3)

Bone Cysts (Phase 2)

Breech Presentation (Phase 3)

Cardiac Output, Low (Phase 3)

Communicable Diseases (Phase 4)

Cysts (Phase 2)

Helicobacter Infections (Phase 4)

Infections (Phase 4)

Intervertebral Disc Degeneration (Phase 3)

Low Back Pain (Phase 3)

Lupus Nephritis (Phase 2)

Metabolic Syndrome (Phase 2)

Nephritis (Phase 2)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Pneumonia (Phase 2)

Spinal Diseases (Phase 2)

Stroke (Phase 4)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 18